Literature DB >> 2143514

Sequential mechanisms of cyclophosphamide-induced skin allograft tolerance including the intrathymic clonal deletion followed by late breakdown of the clonal deletion.

M Eto1, H Mayumi, Y Tomita, Y Yoshikai, Y Nishimura, K Nomoto.   

Abstract

The cellular basis of the transplantation tolerance in a model system of BALB/c (Mls-1b) mice rendered cyclophosphamide (CP)-induced tolerant to DBA/2 (Mls-1a) skin allograft was investigated by assessing V beta 6+ T cells. From our results, three major mechanisms that are essential to the CP-induced skin allograft tolerance were sequentially elucidated. The first mechanism was destruction of donor-Ag-stimulated T cells in the periphery by CP treatment. The second mechanism was intrathymic clonal deletion of donor-reactive T cells, such as V beta 6+ T cells, correlating strongly with intrathymic mixed chimerism. The clonal deletion, however, was not always essential for the maintenance of the skin allografts, because DBA/2 skin survived even after the clonal deletion terminated and V beta 6+ T cells reappeared in the periphery of the recipient BALB/c mice. The third mechanism was generation of tolerogen-specific suppressor T cells, especially in the late stage of the tolerance. In contrast, the clonal anergy that is evidenced by the specific suppression of mixed lymphocyte reaction in the recipient BALB/c mice after injecting with DBA/2 spleen cells alone was not considered as a significant mechanism in prolonging skin allograft survival because such anergic mice showed accelerated rejection of the skin allografts. These results may suggest practical hierarchy of the mechanisms of CP-induced allograft tolerance.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2143514

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  27 in total

1.  Importance of intrathymic mixed chimerism for the maintenance of skin allograft tolerance across fully allogeneic antigens in mice.

Authors:  M Eto; Y Y Kong; J Uozumi; S Naito; K Nomoto
Journal:  Immunology       Date:  1999-03       Impact factor: 7.397

Review 2.  HLA-haploidentical blood or marrow transplantation with high-dose, post-transplantation cyclophosphamide.

Authors:  E J Fuchs
Journal:  Bone Marrow Transplant       Date:  2015-06       Impact factor: 5.483

3.  The Predicted Indirectly Recognizable HLA Epitopes (PIRCHE) Score for HLA Class I Graft-versus-Host Disparity Is Associated with Increased Acute Graft-versus-Host Disease in Haploidentical Transplantation with Post-Transplantation Cyclophosphamide.

Authors:  Joseph Rimando; Michael Slade; John F DiPersio; Peter Westervelt; Feng Gao; Chang Liu; Rizwan Romee
Journal:  Biol Blood Marrow Transplant       Date:  2019-09-26       Impact factor: 5.742

4.  Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS.

Authors:  Christopher G Kanakry; Hua-Ling Tsai; Javier Bolaños-Meade; B Douglas Smith; Ivana Gojo; Jennifer A Kanakry; Yvette L Kasamon; Douglas E Gladstone; William Matsui; Ivan Borrello; Carol Ann Huff; Lode J Swinnen; Jonathan D Powell; Keith W Pratz; Amy E DeZern; Margaret M Showel; Michael A McDevitt; Robert A Brodsky; Mark J Levis; Richard F Ambinder; Ephraim J Fuchs; Gary L Rosner; Richard J Jones; Leo Luznik
Journal:  Blood       Date:  2014-10-14       Impact factor: 22.113

5.  Treatment of hematological malignancies with nonmyeloablative, HLA-haploidentical bone marrow transplantation and high dose, post-transplantation cyclophosphamide.

Authors:  Ashley T Munchel; Yvette L Kasamon; Ephraim J Fuchs
Journal:  Best Pract Res Clin Haematol       Date:  2011-07-13       Impact factor: 3.020

6.  Efficacy and limitations of natural killer cell depletion in cyclophosphamide-induced tolerance.

Authors:  Ichiro Shimizu; Yukihiro Tomita; Shinji Okano; Toshiro Iwai; Takashi Kajiwara; Tatsushi Onzuka; Ryuji Tominaga
Journal:  Surg Today       Date:  2007-01-01       Impact factor: 2.549

7.  Direct evidence for clonal destruction of allo-reactive T cells in the mice treated with cyclophosphamide after allo-priming.

Authors:  T Maeda; M Eto; Y Nishimura; K Nomoto; Y Y Kong; K Nomoto
Journal:  Immunology       Date:  1993-01       Impact factor: 7.397

Review 8.  Modern approaches to HLA-haploidentical blood or marrow transplantation.

Authors:  Christopher G Kanakry; Ephraim J Fuchs; Leo Luznik
Journal:  Nat Rev Clin Oncol       Date:  2015-08-25       Impact factor: 66.675

Review 9.  Transplantation tolerance: from theory to clinic.

Authors:  Ephraim J Fuchs
Journal:  Immunol Rev       Date:  2014-03       Impact factor: 12.988

Review 10.  High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation.

Authors:  Leo Luznik; Ephraim J Fuchs
Journal:  Immunol Res       Date:  2010-07       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.